Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Thymoma and Thymic Carcinoma
About this trial
This is an interventional treatment trial for Thymoma and Thymic Carcinoma focused on measuring thymoma, thymic carcinoma, adjuvant radiotherapy, adjuvant radiochemotherapy, incomplete resection
Eligibility Criteria
Inclusion Criteria:
18~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow, hepatic, and renal function;Patients receive incomplete resection within 3 months; Written informed consent.
Exclusion Criteria:
Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.
Sites / Locations
- Kailiang WuRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Sham Comparator
Radiochemotherapy
radiotherapy
adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)